Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine for colorectal cancer prevention in Lynch syndrome
MOH_2018-12-09_004831Phase 2Completed
- Sponsor
- פרופ' ירון ניב
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Salcrozine in hereditary nonpolyposis colorectal cancer (HNPCC) (3 arms), sponsored by פרופ' ירון ניב. Primary endpoint: Colorectal neoplasia prevention. Started Jul 2016; status: completed.
02
Drugs
Salcrozine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)
Beyond the preview
Go deeper on MOH_2018-12-09_004831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-09_004831.